Should All Low-Grade Ductal Carcinoma In Situ Be Excised? Implications and Challenges of the COMET Trial

Authors

DOI:

https://doi.org/10.14740/wjon2562

Abstract

N/A

Author Biography

  • Yoshiya Horimoto, Tokyo Medical University

    Department of Breast Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan

Downloads

Published

2025-03-25

Issue

Section

Letter to the Editor

How to Cite

1.
Kusama H, Horimoto Y, Takabe K, Ishikawa T. Should All Low-Grade Ductal Carcinoma In Situ Be Excised? Implications and Challenges of the COMET Trial. World J Oncol. 2025;16(2):239-241. doi:10.14740/wjon2562